Provides an overview of fixed combination antihypertensive therapies available in the Russian Federation, highlighting the benefits of ARB and diuretic combinations like candesartan and hydrochlorothiazide.
Answers are grounded in this paper and cite their sources.
Multiple fixed combinations registered in Russia extend initial therapy options; leaves open comparative outcome data.
Hypertension remains the cornerstone of the cardiovascular continuum. An increasing number of patients receive a combination antihypertensive therapy to achieve target blood pressure, expanding indications for combination therapy at the onset of treatment. Constantly growing market of fixed combinations (FC) of antihypertensive drugs. The article gives an overview of the FC, registered in the Russian Federation, discussed the clinical situation for the preferential destination of a FC. A more detailed analysis of FC comprising the angiotensin II receptor blocker and diuretics, in particular, discusses the benefits of FC comprising angiotensin II receptor blocker candesartan and hydrochlorothiazide.
No takes yet. Share an insight, caveat, or question.
Морозова et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: